Table 5.
Multivariable hazard ratios (and 95% CIs) for the association of incident breast cancer and BMI among non-HT users at baseline
| Factor, model | Quantile 1 | Quantile 2 | Quantile 3 | P trend |
|---|---|---|---|---|
| BMI | ||||
| Category cutpoints, kg/m2 | ≤24.9 | 25.0–29.9 | ≥30.0 | |
| No. case patients /No. subcohort members | 135/162 | 135/155 | 137/116 | |
| Base model* | 1.00 (referent) | 1.17 (0.81 to 1.69) | 1.87 (1.25 to 2.80) | .003 |
| Base + estradiol | 1.00 (referent) | 1.13 (0.77 to 1.64) | 1.69 (1.11 to 2.59) | .018 |
| Base + insulin | 1.00 (referent) | 0.89 (0.59 to 1.34) | 1.35 (0.85 to 2.17) | .201 |
| Base + CRP | 1.00 (referent) | 1.01 (0.67 to 1.52) | 1.34 (0.82 to 2.18) | .251 |
| Base + insulin + CRP | 1.00 (referent) | 0.79 (0.51 to 1.23) | 1.05 (0.61 to 1.81) | .823 |
| Base + estradiol + insulin + CRP | 1.00 (referent) | 0.74 (0.47 to 1.17) | 0.91 (0.52 to 1.61) | .780 |
*Base model adjusted for age, race/ethnicity, alcohol consumption, family history of breast cancer, parity, years of menstrual cycling, age at first child’s birth, history of benign breast disease, and physical activity. All statistical tests were two-sided. BMI = body mass index; CI = confidence interval; CRP = C-reactive protein; HT = hormone therapy.